Skip to main content
Terug
Watch Compare

TENAX THERAPEUTICS, INC.

Datakwaliteit: 100%
TENX
Nasdaq Manufacturing Chemicals
€ 14,43
▼ € 0,54 (-3,58%)
Marktkapitalisatie: 260,72 M
Prijs
€ 15,16
Marktkapitalisatie
260,72 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -35,80 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-52,72%
Boven sectorgemiddelde (-53,47%)
ROIC-44,65%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio15,58
Interest CoverageN/A

Waardering

PE (TTM)
-4,96
Onder sectorgemiddelde (-1,48)
P/B Ratio2,71
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -5,0 -1,5
P/B 2,7 1,6
ROE % -52,7 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

7 analisten
Buy
Huidig
€ 14,43
+105.0%
Koersdoel
€ 29,57
€ 20,00
€ 30,00
€ 35,00
Vooruitzicht
Forward K/W -9,87
Forward WPA -€ 1,46
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 1,46
-€ 1,82 – -€ 1,27
 0,0 5
FY2026 -€ 1,56
-€ 1,83 – -€ 1,36
 0,0 6

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,42 -€ 0,38 +8,4%
Q32025 -€ 1,12 -€ 0,40 +64,4%
Q22025 -€ 0,45 -€ 0,27 +39,7%
Q12025 -€ 0,41 -€ 0,28 +31,7%

ETFs Holding This Stock

BRUSX BRUSX
0,60% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -52,60 M
ROE -52,72% ROA -50,41%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -35,80 M
ROIC -44,65% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 15,58
Interest Coverage N/A Asset Turnover 0,00
Working Capital 96,21 M Tangible Book Value 96,21 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,96 Forward P/E N/A
P/B Ratio 2,71 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -13,73%
Market Cap 260,72 M Enterprise Value 161,32 M
Per Share
EPS (Diluted TTM) -1,34 Revenue / Share 0,00
FCF / Share -2,08 OCF / Share -2,08
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 68,06%
SBC-Adj. FCF -50,17 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 — — —
Net Income -52,60 M -17,60 M 7,71 M -11,05 M -32,47 M
EPS (Diluted) -1,34 -1,15 — — —
Gross Profit — — — — —
Operating Income -56,39 M -19,49 M 8,23 M -11,05 M 32,73 M
EBITDA — — — — —
R&D Expenses 32,67 M 12,71 M 3,23 M 5,38 M 25,15 M
SG&A Expenses — — — — 7,58 M
D&A — 0,0 7.570,0 5.143,0 4.116,0
Interest Expense 0,0 23.000,0 23.967,0 4.443,0 949,0
Income Tax 0,0 0,0 — 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 104,23 M 96,69 M 11,68 M 3,40 M 5,99 M
Total Liabilities 7,16 M 4,69 M 3,59 M 1,91 M 1,75 M
Shareholders' Equity 97,07 M 91,99 M 8,10 M 1,49 M 4,24 M
Total Debt — — — — —
Cash & Equivalents 97,60 M 94,90 M — 2,12 M 5,58 M
Current Assets 104,23 M 96,69 M 11,68 M 3,21 M 5,69 M
Current Liabilities 7,16 M 4,69 M 3,59 M 1,85 M 1,56 M